Skip to main content
. 2021 Feb 4;296:100376. doi: 10.1016/j.jbc.2021.100376

Figure 6.

Figure 6

Knockdown of lnc-ORA rescues Dex-induced muscle atrophy in vitro.A, morphology of C2C12 cells induced by Dex. The scale bar represents 200 μm. B, level of lnc-ORA in atrophy myotube. C, protein levels of MuRF1 and MAFbx (n = 3). D, quantitation of protein levels in C (n = 3). E, immunofluorescence staining of MyHC and DAPI (nuclei) after cotreatment of silnc-ORA and Dex. The scale bar represents 100 μm. F, Western blot detection of MuRF1, MAFbx, MyHC, and MyoD after cotreatment with silnc-ORA and Dex (n = 3). G, quantitation of protein levels in F (n = 3). Data represent the mean ± SD. ∗p < 0.05; ∗∗p < 0.01. DAPI, 4′,6-diamidino-2-phenylindole; Dex, dexamethasone; lnc, long noncoding; lnc-ORA, obesity-related lncRNA; MAFbx, muscle atrophy F-box; MuRF1, muscle RING finger 1; MyHC, myosin heavy chain; MyoD, myogenic differentiation 1; silnc-ORA, siRNA-lnc-ORA.